BMS claims Phase 2 success for GPRC5D-directed CAR-T in myeloma
Bristol Myers Squibb claims Phase 2 success for a GPRC5D-targeted CAR-T therapy in multiple myeloma, underscoring the potential of this target while noting ongoing questions about durability and outcomes after progression.